JP2005512976A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005512976A5 JP2005512976A5 JP2003537650A JP2003537650A JP2005512976A5 JP 2005512976 A5 JP2005512976 A5 JP 2005512976A5 JP 2003537650 A JP2003537650 A JP 2003537650A JP 2003537650 A JP2003537650 A JP 2003537650A JP 2005512976 A5 JP2005512976 A5 JP 2005512976A5
- Authority
- JP
- Japan
- Prior art keywords
- dsrna
- type
- strand
- sequence
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 16
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims 22
- 239000002773 nucleotide Substances 0.000 claims 21
- 125000003729 nucleotide group Chemical group 0.000 claims 21
- 108090000623 proteins and genes Proteins 0.000 claims 21
- 230000000295 complement effect Effects 0.000 claims 13
- 230000015572 biosynthetic process Effects 0.000 claims 8
- 108010050808 Procollagen Proteins 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 230000003176 fibrotic effect Effects 0.000 claims 6
- 238000001802 infusion Methods 0.000 claims 4
- 238000002347 injection Methods 0.000 claims 4
- 239000007924 injection Substances 0.000 claims 4
- 102000008490 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Human genes 0.000 claims 3
- 108010020504 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Proteins 0.000 claims 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 3
- 102100031168 CCN family member 2 Human genes 0.000 claims 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 3
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 claims 3
- 108091034117 Oligonucleotide Proteins 0.000 claims 3
- 108090000630 Oncostatin M Proteins 0.000 claims 3
- 102000004140 Oncostatin M Human genes 0.000 claims 3
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 claims 3
- 102000004669 Protein-Lysine 6-Oxidase Human genes 0.000 claims 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 3
- 108091005735 TGF-beta receptors Proteins 0.000 claims 3
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 claims 3
- 102000014172 Transforming Growth Factor-beta Type I Receptor Human genes 0.000 claims 3
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 claims 3
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 claims 3
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 claims 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 210000002744 extracellular matrix Anatomy 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 230000009368 gene silencing by RNA Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 3
- 229920002477 rna polymer Polymers 0.000 claims 3
- 230000036573 scar formation Effects 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 3
- 206010023421 Kidney fibrosis Diseases 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 230000035876 healing Effects 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 231100000241 scar Toxicity 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 102000004079 Prolyl Hydroxylases Human genes 0.000 claims 1
- 108010043005 Prolyl Hydroxylases Proteins 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 101100505328 Colletotrichum trifolii CTG1 gene Proteins 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10155280 | 2001-10-26 | ||
| DE10158411 | 2001-11-29 | ||
| DE10160151A DE10160151A1 (de) | 2001-01-09 | 2001-12-07 | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
| PCT/EP2002/000152 WO2002055693A2 (de) | 2001-01-09 | 2002-01-09 | Verfahren zur hemmung der expression eines zielgens |
| PCT/EP2002/000151 WO2002055692A2 (de) | 2001-01-09 | 2002-01-09 | Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung |
| PCT/EP2002/011972 WO2003035083A1 (de) | 2001-10-26 | 2002-10-25 | Medikament zur behandlung einer fibrotischen erkrankung durch rna interferenz |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005512976A JP2005512976A (ja) | 2005-05-12 |
| JP2005512976A5 true JP2005512976A5 (enExample) | 2006-03-09 |
Family
ID=39189390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003537650A Pending JP2005512976A (ja) | 2001-10-26 | 2002-10-25 | Ｒｎａ干渉により線維化疾患を処置するための医薬 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20080070856A1 (enExample) |
| JP (1) | JP2005512976A (enExample) |
| CN (1) | CN1604783A (enExample) |
| WO (2) | WO2003035083A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9340786B2 (en) | 2010-03-24 | 2016-05-17 | Rxi Pharmaceuticals Corporation | RNA interference in dermal and fibrotic indications |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
| US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| US7423142B2 (en) | 2001-01-09 | 2008-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
| US8546143B2 (en) | 2001-01-09 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
| US7745418B2 (en) | 2001-10-12 | 2010-06-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting viral replication |
| DE10163098B4 (de) | 2001-10-12 | 2005-06-02 | Alnylam Europe Ag | Verfahren zur Hemmung der Replikation von Viren |
| DE10202419A1 (de) | 2002-01-22 | 2003-08-07 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens |
| EP1486564A1 (de) * | 2003-06-13 | 2004-12-15 | Ribopharma AG | SiRNA mit erhöhter Stabilität in Serum |
| ES2761262T3 (es) | 2003-06-13 | 2020-05-19 | Alnylam Europe Ag | Acido ribonucleico bicatenario con elevada eficacia en un organismo |
| US20070004657A1 (en) * | 2003-11-17 | 2007-01-04 | Orna Mor | Diagnosis and treatment of kidney fibrosis and other fibrotic diseases |
| WO2005053725A2 (en) * | 2003-11-26 | 2005-06-16 | The Queen's University Of Belfast | Cancer treatment |
| JP4543189B2 (ja) * | 2004-03-10 | 2010-09-15 | 学校法人日本医科大学 | ＴＧＦβ１レセプターＩＩ型に対するＲＮＡｉとして作用するＲＮＡ配列 |
| FR2898908A1 (fr) | 2006-03-24 | 2007-09-28 | Agronomique Inst Nat Rech | Procede de preparation de cellules aviaires differenciees et genes impliques dans le maintien de la pluripotence |
| WO2010021720A1 (en) | 2008-08-19 | 2010-02-25 | Nektar Therapeutics | Conjugates of small-interfering nucleic acids |
| US8946172B2 (en) * | 2008-08-25 | 2015-02-03 | Excaliard Pharmaceuticals, Inc. | Method for reducing scarring during wound healing using antisense compounds directed to CTGF |
| KR101877698B1 (ko) | 2008-08-25 | 2018-07-12 | 엑스칼리아드 파마슈티컬즈, 인코포레이티드 | 결합 조직 성장 인자에 대한 안티센스 올리고뉴클레오타이드 및 그의 용도 |
| CA2753338A1 (en) * | 2008-09-22 | 2010-03-25 | Rxi Pharmaceuticals Corporation | Neutral nanotransporters |
| CN102666587A (zh) | 2009-07-02 | 2012-09-12 | 菲布罗根有限公司 | 用于治疗肌营养不良的方法 |
| WO2011035065A1 (en) | 2009-09-17 | 2011-03-24 | Nektar Therapeutics | Monoconjugated chitosans as delivery agents for small interfering nucleic acids |
| US20120244169A1 (en) | 2009-11-06 | 2012-09-27 | Fibrogen, Inc. | Treatment for Radiation-Induced Disorders |
| EP3578183B1 (en) | 2010-03-24 | 2021-09-08 | Phio Pharmaceuticals Corp. | Rna interference in ocular indications |
| CA2801066C (en) * | 2010-06-02 | 2021-02-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods directed to treating liver fibrosis |
| AR083445A1 (es) | 2010-10-14 | 2013-02-27 | Univ Mie | siARN CONTRA LA FIBROSIS |
| US20140134181A1 (en) | 2010-11-05 | 2014-05-15 | Kenneth E. Lipson | Treatment Method For Lung Remodeling Diseases |
| EP2670411B1 (en) | 2011-02-02 | 2019-04-10 | Excaliard Pharmaceuticals, Inc. | Antisense compounds targeting connective tissue growth factor (ctgf) for use in a method of treating keloids or hypertrophic scars |
| US10337009B2 (en) | 2014-12-15 | 2019-07-02 | Bonac Corporation | Single-stranded nucleic acid molecule for inhibiting TGF-β1 expression |
| WO2017100193A1 (en) | 2015-12-10 | 2017-06-15 | Fibrogen, Inc. | Methods for treatment of motor neuron diseases |
| KR102666000B1 (ko) * | 2016-07-29 | 2024-05-14 | 서울대학교 산학협력단 | cFLIP siRNA를 포함하는 인터페론 베타 저항성 암 질환 치료용 또는 감작용 조성물 |
| CN109432047B (zh) * | 2018-10-29 | 2021-07-20 | 中国药科大学 | 一种逆转肺纤维化纳米制剂及其制备方法 |
| US20200369759A1 (en) | 2019-05-23 | 2020-11-26 | Fibrogen, Inc. | Methods of treatment of muscular dystrophies |
| CN112843253B (zh) * | 2021-01-13 | 2023-07-14 | 上海交通大学 | 一种基因/药物复合脂质制剂及其制备方法和用途 |
| WO2024262593A1 (ja) * | 2023-06-22 | 2024-12-26 | 公益財団法人川崎市産業振興財団 | 核酸の血中安定性を向上させ、標的化効率を向上させる方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6984594A (en) * | 1993-06-15 | 1995-01-17 | Hun Taeg Chung | Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof |
| DE19631919C2 (de) * | 1996-08-07 | 1998-07-16 | Deutsches Krebsforsch | Anti-Sinn-RNA mit Sekundärstruktur |
| US6242569B1 (en) * | 1997-02-05 | 2001-06-05 | Tularik, Inc. | Regulators of apoptosis |
| DE19713393C2 (de) * | 1997-04-01 | 2002-12-05 | Apotech Res & Dev Ltd | Flip-Gen und Flip-Protein |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AU4411499A (en) * | 1998-06-05 | 1999-12-20 | Human Genome Sciences, Inc. | Connective tissue growth factor-4 |
| DE69832204T2 (de) * | 1998-10-08 | 2006-07-27 | Stichting Voor De Technische Wetenschappen | Auf peptiden basierende trägervorrichtungen für stellatzellen |
| WO2000027868A2 (en) * | 1998-11-06 | 2000-05-18 | Fibrogen, Inc. | Connective tissue growth factor (ctgf) and methods of use |
| AU775391B2 (en) * | 1998-12-14 | 2004-07-29 | Fibrogen, Inc. | Connective tissue growth factor fragments and methods and uses thereof |
| DE19956568A1 (de) * | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| US6436909B1 (en) * | 1999-09-17 | 2002-08-20 | Isis Pharmaceuticals, Inc. | Antisense inhibition of transforming growth factor-β expression |
| GB9927444D0 (en) * | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| DK2796553T3 (da) * | 2000-03-30 | 2019-09-30 | Whitehead Inst Biomedical Res | Rna-sekvensspecifikke formidlere af rna-interferens |
| CZ302719B6 (cs) * | 2000-12-01 | 2011-09-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití |
-
2002
- 2002-10-25 WO PCT/EP2002/011972 patent/WO2003035083A1/de not_active Ceased
- 2002-10-25 WO PCT/EP2002/011968 patent/WO2003035868A1/de not_active Ceased
- 2002-10-25 JP JP2003537650A patent/JP2005512976A/ja active Pending
- 2002-10-25 CN CNA028251636A patent/CN1604783A/zh active Pending
-
2007
- 2007-05-11 US US11/747,549 patent/US20080070856A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9340786B2 (en) | 2010-03-24 | 2016-05-17 | Rxi Pharmaceuticals Corporation | RNA interference in dermal and fibrotic indications |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005512976A5 (enExample) | ||
| ES2595079T3 (es) | Ácido ribonucleico de interferencia corto (ARNip) | |
| DE69833438T2 (de) | Hiv-spezifische oligonukleotide und verfahren zu deren verwendung | |
| US20220033819A1 (en) | Compositions and methods for treatment of cardiac diseases | |
| JP2005506087A5 (enExample) | ||
| JP2005512976A (ja) | Ｒｎａ干渉により線維化疾患を処置するための医薬 | |
| JP2017533715A (ja) | 調節性ポリヌクレオチド | |
| JP2018517704A (ja) | 筋萎縮性側索硬化症（ＡＬＳ）を処置するためのｍｉＲ−１５５阻害剤 | |
| ES2464731T3 (es) | Compuestos y procedimientos para reducir el reclutamiento y/o migración de células polimorfonucleares | |
| EP3132803B1 (en) | Preventive or therapeutic agent for pain associated with herpes zoster in acute phase | |
| CN112996913A (zh) | 寡聚核酸分子及其应用 | |
| CN119632973A (zh) | 漆黄素制备治疗心脏有关疾病的药物中的应用 | |
| JPWO2017043639A1 (ja) | キメラデコイ | |
| JPWO2021167841A5 (enExample) | ||
| JP2000514438A (ja) | Ｇｒｂ２またはＣｒｋ１へのリポソームアンチセンスオリゴデオキシヌクレオチド標的化による慢性骨髄性白血病細胞増殖の阻害 | |
| WO2020225871A1 (ja) | 食道狭窄抑制剤 | |
| CN110141577A (zh) | miRNA-24-3p核苷酸类似物在制备药物中的应用 | |
| CN115137742A (zh) | 一种用于治疗肥胖症的rna递送系统 | |
| KR20230088810A (ko) | 마이크로rna-29 화합물, 조성물 및 요법에서의 용도 | |
| JP2001515011A (ja) | 肺高血圧症のアンチセンス治療 | |
| CN115414468B (zh) | 一种趋化素样因子1衍生肽在制备镇痛制剂中的应用 | |
| CN101503437B (zh) | 核酸分子si-cypj-4及其在制备抗癌药物中的应用 | |
| AU2023385485A1 (en) | Inhibitory nucleic acids and methods of use thereof | |
| WO2024071480A2 (ko) | 금 나노입자를 유효성분으로 포함하는 혈전성 질환의 예방 또는 치료용 조성물 | |
| CN120361033A (zh) | miRNA-149-5p及其激动剂在制备脓毒症肺损伤治疗药物中的应用 |